Zydus receives Health Canada approval for generic Liothyronine tablets
Zydus Lifesciences has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg.
Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism.
ZDS- Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ.
Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content